

A Smart Partner for Diabetes Management

CONTOUR® NEXT LINK 2.4 from Bayer — the only meter that links to the MiniMed® 640G System[^] to help your patients achieve better glucose control.¹



1. BETTER OUTCOMES FOR PATIENTS

The CONTOUR® NEXT LINK 2.4 meter uses the CONTOUR® NEXT test strip, the newest strip technology from Bayer, to provide your patients with accuracy² and performance.



No Coding™ Technology

Removes the need for patients to code the meter manually, preventing miscoding errors that could produce inaccurate results (by as much as 4.0 mmol/L).³



Multipulse™ Accuracy Technology

Ensures more accurate glucose measurements, even when blood glucose levels are low vs. CONTOUR® LINK. Provides accuracy unaffected by many common interfering substances and medications.⁴



CONTOUR® NEXT test strips

Provides accurate blood glucose readings for your patients. Exceeds ISO 15197:2013 minimum accuracy requirements in the lab.⁵⁻⁶

Percentage of accurate results with the CONTOUR® NEXT LINK 2.4 meter system^{5,6 + †5}

ISO Standard	< 5.6 mmol/L Within ±0.56 mmol/L	> 5.6 mmol/L Within ± 10%	< 5.6 mmol/L Within ±0.83 mmol/L	> 5.6 mmol/L Within ±15%
2013 (section 6:3)	98.4%	99.3%	100%	100%
2013 (section 6:3)	Parkes-Consensus Error Grid results: 100% of the results fall within zone A (having no effect on clinical action) ^{3,5,6}			

2. EASY MANAGEMENT FOR PATIENTS

The CONTOUR® NEXT LINK 2.4 meter wirelessly connects to the MiniMed® 640G system[^] and provides your patients added convenience to manage their diabetes effectively.



Remote Bolusing

Has the option to transmit preset and manual bolus commands to the pump.



Automatic Transfer

Automatically sends blood glucose values to the Bolus Wizard™ feature on MiniMed® 640G, helping to ensure easier bolus dosing.



Easier Sampling

Features Sip-In Sampling™ technology that automatically draws blood into the test chamber. Offers Second-Chance™ sampling that allows patients to add more blood if initial samples are insufficient.

3. SMARTER TRACKING FOR PATIENTS

The CONTOUR® NEXT LINK 2.4 meter connects to Medtronic CareLink® therapy management software, allowing your patients to track their blood glucose control in greater detail.

Medtronic CareLink® upload

Conveniently allows your patients to upload both their meter and pump information to Medtronic CareLink® software, which provides you with detailed logs to optimise therapy adjustments.

Has been shown to help reduce HbA1c among users,⁷ which can lead to reductions in complications

Detailed, easy-to-interpret glucose trend reports conveniently allow you to review patient events and trends



CONTOUR® NEXT LINK 2.4 is the only available meter that works seamlessly with the MiniMed® 640G System[^]. To learn more, contact your Medtronic representative today.



Web: www.medtronic-diabetes.com.au **Email:** australia.diabetes@medtronic.com

Facebook: www.facebook.com/MedtronicDiabetesAUS **Twitter:** @DiabetesANZ **YouTube:** Medtronic Diabetes ANZ

Address: Medtronic Australasia Pty Ltd, 97 Waterloo Road, North Ryde NSW 2113 Australia

Mail: Medtronic Diabetes, PO Box 945, North Ryde, NSW 1670 **Telephone:** 02 9857 9000 **Facsimilie:** 02 9857 9237

24-hour Toll Free: 1800 777 808 **Bayer Toll Free Helpline:** 1800 289 312

References:

[^]Components sold separately. Automated insulin delivery is made possible through combining Medtronic insulin pump and continuous glucose monitoring technology. ¹ISO 15197:2013 section 6.3 requires 95% of results to fall within ± 0.83 mmol/L of a laboratory reference value for blood glucose concentrations < 5.6 mmol/L or within $\pm 15\%$ of a laboratory reference value for blood glucose concentrations ≥ 5.6 mmol/L. Ninety-nine percent of individual glucose measured values are required to fall within zones A and B of the Parkes-Consensus Error Grid for type 1 diabetes. ²Shaded areas are results per ISO standard system accuracy performance criteria.³ ³Not all data shown. ⁴~Please note: In contacting the Diabetes Toll Free, your patients personal and health information may be disclosed to an operator located outside Australia.

1. Compared to multiple daily injections, according to the STAR 3 clinical study: Bergenstal RM, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. *NEJM*. 2010;363:311–320. **2.** Section 7 clinical study. Data on File. Bayer Healthcare, LLC. **3.** Department of Health. A Guide to Blood Glucose Meters on the UK Market. London, England: Department of Health; 2005. **4.** See CONTOUR® NEXT LINK 2.4 package insert for list of substances and medications. **5.** Data on file. Bayer HealthCare LLC. **6.** International Organization for Standardization. In vitro diagnostic test systems—requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. Geneva, Switzerland: International Organization for Standardization; 2013. **7.** Corrivau EA, et al. Effect of CareLink, an internet-based insulin pump monitoring system, on glycemic control in rural and urban children with Type 1 diabetes mellitus. *Ped Diab*. 2008;9(Part II):360-366.

Safety Information: MiniMed® 640G Insulin Pump is indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. In addition, the Enlite™ glucose sensor is indicated for continuous or periodic monitoring of sensor glucose levels in the fluid under the skin, and possible low and high glucose episodes. The pump displays continuous sensor glucose values and stores this data so that it can be analysed to track patterns and improve diabetes management. This data can be downloaded to a computer for analysis of historical sensor glucose values. The continuous sensor glucose values provided by the MiniMed® 640G insulin pump are not intended to be used directly for making therapy adjustments. Rather, they provide an indication that a confirmation fingerstick measurement may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not based on the value displayed by the pump.

Safety Information: Medtronic CareLink® software is intended for use as a tool to help manage diabetes. The purpose of the software is to take information transmitted from insulin pumps, glucose meters and continuous glucose monitoring systems, and turn it into Medtronic CareLink® reports. The reports provide information that can be used to identify trends and track daily activities, such as carbohydrates consumed, meal times, insulin delivery and glucose readings. NOTE: Medtronic CareLink® report data is intended for use as an adjunct in the management of diabetes only and NOT intended to be relied upon by itself. Patients should consult their healthcare providers familiar with the management of diabetes prior to making changes in treatment.

Bayer, the Bayer Cross and Contour are registered trademarks and Sip-in Sampling, No Coding, Multipulse and Second Chance are trademarks of Bayer Healthcare, LLC. MiniMed and Medtronic CareLink are registered trademarks and Bolus Wizard is a trademark of Medtronic MiniMed, Inc.